The global market for glial cell line-derived neurotrophic factors is expected to expand at a rapid pace (2022-2028). The rising incidence of Parkinson's disease (PD) throughout the world is one of the primary reasons driving the market's rise. According to the Parkinson Foundation, almost one million persons in the US suffer with Parkinson's disease, with the number expected to increase to 1.2 million by 2030. Furthermore, approximately 60,000 Americans are diagnosed with Parkinson's disease each year, and the disease affects over 10 million people globally. Parkinson's disease increases with age; nevertheless, only around 4% of those diagnosed with Parkinson's disease are under the age of 50. Men are 1.5 times more likely than women to get Parkinson's disease. As a result of the increasing prevalence of this disease, the need for glial cell line derived neurotrophic factors for therapy is increasing, propelling the global glial cell line derived neurotrophic factor market ahead. The GDNF gene encodes a protein called glial cell-derived neurotrophic factor. GDNF is a tiny protein that aids in the survival of several neuronal types by binding to GFR receptors, notably GFR1.
Browse the full report description of “Global Glial Cell Line Derived Neurotrophic Factor Market Size, Share, and Trend Analysis Report, By Type (GSK-812, LAUR-301, TW-002, AMT-090, and Others), By Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson's Disease, Retinal Degeneration, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/glial-cell-line-derived-neurotrophic-factor-market
Furthermore, ongoing clinical trials for the treatment of Parkinson's disease provide a considerable prospect for market growth. For instance, on January 3, 2020, National Cheng-Kung University Hospital began clinical research examining the efficacy of Hericium Erinaceus Mycelium on Parkinson's disease non-motor symptoms (NMS). The goal of this experiment is to conduct a randomised, controlled trial to see how Hericium Erinaceus mycelium, which is high in Erinacine A, affects Parkinson's disease NMS.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- GlaxoSmithKline plc, Treeway BV, and others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Glial Cell Line Derived Neurotrophic Factor Market Report Segment.
By Type
By Application
Global Glial Cell Line Derived Neurotrophic Factor Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/glial-cell-line-derived-neurotrophic-factor-market